No abstract available
Keywords:
Cost-effective; leukemia; lymphoma; multiple myeloma; pharmacogenomics.
MeSH terms
-
Antineoplastic Agents / economics
-
Antineoplastic Agents / therapeutic use*
-
Cost-Benefit Analysis
-
Drug Approval*
-
Hematologic Neoplasms / drug therapy*
-
Humans
-
United States
-
United States Food and Drug Administration